CoChat
Cited by 268

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial

Open access
Dauvilliers, Yves, Verbraecken, Johan, Partinen, Markku, Hedner, Jan, Saaresranta, Tarja, Georgiev, Ognian, Tiholov, Rumen, Lecomte, Isabelle, Tamisier, Renaud, Lévy, Patrick, Scart-Gres, Catherine, Lecomte, Jeanne-Marie, Schwartz, Jean-Charles, Pépin, Jean-Louis, Attali, Valerie, Bourgin, Patrice, Gagnadoux, Frederic, Baharloo, Farhad, Berg, Soren, Polo, Olli, Hedner, Jan Anders, Peker, Yeksel, Blau, Alexander, Borreguero, Diego Garcia, Puertas Cuesta, Francisco Javier, Belev, Georgi, Ivanov, Yavor, Metev, Hristo, Petkova, Diana, Dokic, Dejan, Marku, Merita Ismajli, Kaeva, Biserka Jokovska, Jankovic, Slavko, Kopitovic, Ivan, Vukcevic, Miodrag · 2020 · American Journal of Respiratory and Critical Care Medicine

Abstract

Abstract Rationale Excessive daytime sleepiness is a common disabling symptom in obstructive sleep apnea syndrome. Objectives To evaluate the efficacy and safety of pitolisant, a selective histamine H3 receptor antagonist with wake-promoting effects, for the treatment of daytime sleepiness in patients with moderate to severe obstructive sleep apnea refusing continuous positive airway pressure treatment. Methods In an international, multicenter, double-blind, randomized (3:1), placebo-controlled, parallel-design trial, pitolisant was individually titrated at up to 20 mg/d over 12 weeks. The primary endpoint was the change in the Epworth Sleepiness Scale score. Key secondary endpoints were maintenance of wakefulness assessed on the basis of the Oxford Sleep Resistance test, safety, Clinical Global Impression of severity, patient’s global opinion, EuroQol quality-of-life questionnaire, and Pichot fatigue questionnaire. Measurements and Main Results A total of 268 patients with obstructive sleep apnea (75% male; mean age, 52 yr; apnea–hypopnea index, 49/h; baseline sleepiness score, 15.7) were randomized (200 to pitolisant and 68 to placebo) and analyzed on an intention-to-treat basis. The Epworth Sleepiness Scale score was reduced more with pitolisant than with placebo (−2.8; 95% confidence interval, −4.0 to −1.5; P < 0.001). Wake maintenance tests were not improved. The Pichot fatigue score was reduced with pitolisant. The overall impact of pitolisant was confirmed by both physicians’ and patients’ questionnaires. Adverse event incidence, mainly headache, insomnia, nausea, and vertigo, was similar in the pitolisant and placebo groups (29.5% and 25.4%, respectively), with no cardiovascular or other significant safety concerns. Conclusions Pitolisant significantly reduced self-reported daytime sleepiness and fatigue and improved patient-reported outcomes and physician disease severity assessment in sleepy patients with obstructive sleep apnea refusing or nonadherent to continuous positive airway pressure. Clinical trial registered with www.clinicaltrials.gov (NCT01072968) and EU Clinical Trials Register (EudraCT 2009-017251-94).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.201907-1284oc

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 268

Metadata

Authors
Dauvilliers, Y., Verbraecken, J., Partinen, M., Hedner, J., Saaresranta, T., Georgiev, O., Tiholov, R., Lecomte, I., Tamisier, R., Lévy, P., Scart-Gres, C., Lecomte, J.-M., Schwartz, J.-C., Pépin, J.-L., Attali, V., Bourgin, P., Gagnadoux, F., Baharloo, F., Berg, S., Polo, O., Hedner, J. A., Peker, Y., Blau, A., Borreguero, D. G., Puertas Cuesta, F. J., Belev, G., Ivanov, Y., Metev, H., Petkova, D., Dokic, D., Marku, M. I., Kaeva, B. J., Jankovic, S., Kopitovic, I., & Vukcevic, M.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2020-05-01
Volume
201
Issue
9
Pages
1135-1145
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W3000649099
Cited by
268
References
32
FWCI
29.42
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.